Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations

Critical Reviews in Oncology/Hematology

Volumn 53, Issue 1, 2005, Pages 25-34

  Fojo, Tito ^a   Farrell, Nick ^b   Ortuzar, Waldo ^a   Tanimura, Hideyuki ^a   Weinstein, John ^a   Myers, Timothy G ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Bioinformatics; Carboplatin; Chemotherapy; Cisplatin; Drug discovery; Drug screen; NCI 60; Oxaliplatin; Platinum

Indexed keywords

ALKYLATING AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; NSC 141253N; NSC 146067A; NSC 263158; NSC 364433H; NSC 541054; NSC 545353; NSC 614887O; NSC 623318C; NSC 632790; NSC 632791; NSC 632819; NSC 638728; NSC 645356; NSC 647616O; NSC 662253; OXALIPLATIN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MATHEMATICAL ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 10644259645     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.09.008     Document Type: Review

References (36)

1. B. Rosenberg, L. VanCamp, J.E. Trosko, and V.H. Mansour Platinum compounds: a new class of potent antitumour agents Nature 222 1969 385 386
2. D.J. Higby, H.J. Wallace Jr., and J.F. Holland cis- Diamminedichloroplatinum (NSC-119875): a phase I study Cancer Chemother Rep 57 1973 459 463
3. M. Hayat, M. Bayssas, G. Brule, P. Cappelaere, A. Cattan, and J. Chauvergne cis-Diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial Nouv Presse Med 8 1979 1231 1234
4. P.D. Bonomi, R.E. Slayton, and J. Wolter Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas Cancer Treat Rep 62 1978 1211 1213
5. T. Thigpen, H. Shingleton, H. Homesley, L. LaGasse, and J. Blessing cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group Cancer Treat Rep 63 1979 1549 1555
6. L.H. Einhorn, and J.P. Donohue Chemotherapy for disseminated testicular cancer Urol Clin North Am 4 1977 407 426
7. R. De Jager, E. Longeval, and J. Klastersky High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium) Cancer Treat Rep 64 1980 1341 1346
8. Y. Inuyama, and C. Takeda A cooperative phase II study of cisplatin in patients with head and neck cancer Gan To Kagaku Ryoho 13 1986 232 238
9. W.W. ten Bokkel Huinink, M.E. van der Burg, A.T. van Oosterom, J.P. Neijt, M. George, and J.P. Guastalla Carboplatin in combination therapy for ovarian cancer Cancer Treat Rev 15 Suppl. B 1988 9 15
10. M.C. Christian The current status of new platinum analogs Semin Oncol 19 1992 720 733 [related articles, links (abstract)]
11. F. Levi, B. Perpoint, C. Garufi, C. Focan, P. Chollet, and P. Depres-Brummer Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate Eur J Cancer 29A 1993 1280 1284
12. A. de Gramont, J. Vignoud, C. Tournigand, C. Louvet, T. Andre, and C. Varette Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer Eur J Cancer 33 1997 214 219 [related articles, links (abstract)]
13. P. Soulie, E. Raymond, S. Brienza, and E. Cvitkovic Oxaliplatin: the first DACH platinum in clinical practice Bull Cancer 84 1997 665 673
14. E. Diaz-Rubio, J. Sastre, A. Zaniboni, R. Labianca, H. Cortes-Funes, and F. de Braud Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study Ann Oncol 9 1998 105 108
15. L.R. Kelland An update on satraplatin: the first orally available platinum anticancer drug Expert Opin Invest Drugs 9 2000 1373 1382
16. C.F. O'Neill, B. Koberle, J.R. Masters, and L.R. Kelland Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin Br J Cancer 81 1999 1294 1303
17. S.Y. Sharp, C.F. O'Neill, P. Rogers, F.E. Boxall, and L.R. Kelland Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin Eur J Cancer 38 2002 2309 2315
18. P. Beale, I. Judson, A. O'Donnell, J. Trigo, C. Rees, and F. Raynaud A Phase I clinical and pharmacological study of cis-diamminedichloro(2- methylpyridine) platinum II (AMD473) Br J Cancer 88 2003 1128 1134
19. L.R. Kelland New platinum drugs: the pathway to oral therapy L.R. Kelland N. Farrell Platinum-Based Drugs in Cancer Therapy 2000 Humana Press 299 320
20. Farrell N. Polynuclear platinum drugs. Met Ions Biol Syst 2004;41 [in press].
21. C. Gourley, J. Cassidy, C. Edwards, L. Samuel, D. Bisset, and G. Camboni A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer Cancer Chemother Pharmacol 53 2004 95 101
22. O. Rixe, W. Ortuzar, M. Alvarez, R. Parker, E. Reed, and K. Paull Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel Biochem Pharmacol 52 1996 1855 1865
23. J.N. Weinstein, T. Myers, J. Buolamwini, K. Raghavan, V.N. Viswanadhan, and J. Licht Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS Stem Cells 12 1994 13 22
24. J.N. Weinstein, T.G. Myers, P.M. O'Connor, S.H. Friend, A.J. Fornace, and K.W. Kohn An information-intensive approach to the molecular pharmacology of cancer Science 275 1997 343 349
25. T.G. Myers, M. Waltham, G. Li, J.K. Buolamwini, D.A. Scudiero, and L.V. Rubinstein A protein expression database for the molecular pharmacology of cancer Electrophoresis 18 1997 647 653
26. M. Mishima, G. Samimi, A. Kondo, X. Lin, and S.B. Howell The cellular pharmacology of oxaliplatin resistance Eur J Cancer 38 2002 1405 1412
27. K.D. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, and L. Rubinstein Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm J Natl Cancer Inst 81 1989 1088 1092
28. Kung A, Strickmann DB, Galanski M, Keppler BK. Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5′-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. J Inorg Biochem 2000; 86:691-8.
29. B. Legallicier, C. Leclere, C. Monteil, V. Elkaz, J.P. Morin, and J.P. Fillastre The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells Drugs Exp Clin Res 22 1996 41 50 [related articles, links (abstract)]
30. E. Raymond, S.G. Chaney, A. Taamma, and E. Cvitkovic Oxaliplatin: a review of preclinical and clinical studies Ann Oncol 9 1998 1053 1071
31. N. Farrell Current status of structure-activity relationships of platinum anticancer drugs. Activation of the trans geometry Metal Ions Biol Syst 32 1966 603
32. Farrell N, Povirk LF, Dange Y, Kohlhagen G, Khan QA, Pommier Y, Gewirtz DA. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem Pharmacol [submitted for publication].
33. M. Alvarez, K. Paull, A. Monks, C. Hose, J.S. Lee, and J. Weinstein Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen J Clin Invest 95 1995 2205 2214
34. J.S. Lee, K. Paull, M. Alvarez, C. Hose, A. Monks, and M. Grever Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen Mol Pharmacol 46 1994 627 638
35. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
36. P.A. Andrews, and S.B. Howell Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance Cancer Cells 2 1990 35 43